These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 9016328)

  • 1. Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.
    Wityak J; Sielecki TM; Pinto DJ; Emmett G; Sze JY; Liu J; Tobin AE; Wang S; Jiang B; Ma P; Mousa SA; Wexler RR; Olson RE
    J Med Chem; 1997 Jan; 40(1):50-60. PubMed ID: 9016328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
    Olson RE; Sielecki TM; Wityak J; Pinto DJ; Batt DG; Frietze WE; Liu J; Tobin AE; Orwat MJ; Di Meo SV; Houghton GC; Lalka GK; Mousa SA; Racanelli AL; Hausner EA; Kapil RP; Rabel SR; Thoolen MJ; Reilly TM; Anderson PS; Wexler RR
    J Med Chem; 1999 Apr; 42(7):1178-92. PubMed ID: 10197962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists.
    Xue CB; Wityak J; Sielecki TM; Pinto DJ; Batt DG; Cain GA; Sworin M; Rockwell AL; Roderick JJ; Wang S; Orwat MJ; Frietze WE; Bostrom LL; Liu J; Higley CA; Rankin FW; Tobin AE; Emmett G; Lalka GK; Sze JY; Di Meo SV; Mousa SA; Thoolen MJ; Racanelli AL; Olson RE
    J Med Chem; 1997 Jun; 40(13):2064-84. PubMed ID: 9207948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.
    Mousa SA; Forsythe M; Wityak J; Bozarth J; Mu DX
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):441-8. PubMed ID: 9514190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
    Hutchinson JH; Cook JJ; Brashear KM; Breslin MJ; Glass JD; Gould RJ; Halczenko W; Holahan MA; Lynch RJ; Sitko GR; Stranieri MT; Hartman GD
    J Med Chem; 1996 Nov; 39(23):4583-91. PubMed ID: 8917647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
    Mousa SA; Bozarth JM; Lorelli W; Forsythe MS; Thoolen MJ; Slee AM; Reilly TM; Friedman PA
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1277-84. PubMed ID: 9732389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antiplatelet effects of an isoxazole series of glycoprotein IIb/IIIa antagonists.
    Xue CB; Roderick J; Mousa S; Olson RE; DeGrado WF
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3499-504. PubMed ID: 9934460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists.
    Sielecki TM; Liu J; Mousa SA; Racanelli AL; Hausner EA; Wexler RR; Olson RE
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2201-4. PubMed ID: 11514170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
    J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists.
    Sielecki TM; Wityak J; Liu J; Mousa SA; Thoolen M; Wexler RR; Olson RE
    Bioorg Med Chem Lett; 2000 Mar; 10(5):449-52. PubMed ID: 10743945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolidines.
    Confalone PN; Jin F; Mousa SA
    Bioorg Med Chem Lett; 1999 Jan; 9(1):55-8. PubMed ID: 9990456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of salt form on chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms.
    Badawy SI
    Int J Pharm; 2001 Jul; 223(1-2):81-7. PubMed ID: 11451634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor.
    Mutlib AE; Diamond S; Shockcor J; Way R; Nemeth G; Gan L; Christ DD
    Xenobiotica; 2000 Nov; 30(11):1091-110. PubMed ID: 11197070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of cis and trans isomers of an isoxazoline ring-hydroxylated metabolite of roxifiban, a platelet glycoprotein IIb/IIIa receptor antagonist.
    Batt DG; Houghton GC; Daneker WF; Jadhav PK
    J Org Chem; 2000 Nov; 65(23):8100-4. PubMed ID: 11073629
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
    Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs.
    Furuya A; Nozawa M; Gotoh J; Jingu S; Akimoto M; Higuchi S; Suwa T; Ogata H
    J Pharm Pharmacol; 2002 Jul; 54(7):921-7. PubMed ID: 12162710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
    Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
    J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
    Storey RF; May JA; Wilcox RG; Heptinstall S
    Thromb Haemost; 1999 Oct; 82(4):1307-11. PubMed ID: 10544919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.